Sumary of SSRI antidepressants observed to protect COVID-19 patients from death:
- Novel research from the US has identified that SSRI antidepressants may possess qualities that help to reduce deaths in COVID-19 patients.
- The findings of the study supplement previous evidence that SSRI antidepressants can implement beneficial effects against the most severe symptoms of COVID-19. However, a more extensive, randomised clinical trial will be required to prove this.
- Marina Sirota, PhD, an associate professor of paediatrics and a member of the Bakar Computational Health Sciences Institute (BCHSI) at UC San Francisco, said: “We can’t tell if the drugs are causing these effects, but the statistical analysis is showing significant association.
- ” COVID-19 protection The Researchers employed electronic health records from the Cerner Real World COVID-19 de-identified database to perform their investigation.
- This enabled the researchers to understand the effects of age, race, sex, ethnicity, and comorbidities associated with COVID-19, such as heart disease and diabetes, in addition to other medications the patients were taking.
- Impacts of SSRI antidepressants The results of the study illuminated that individuals taking fluoxetine were 28% less likely to die from COVID-19, and those taking either fluoxetine or another type of SSRI called fluvoxamine were 26% less likely to die.